Quest Diagnostics Announces Organizational Changes to Accelerate Growth and Drive Operational Excellence

Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) announced key organizational changes to enhance operational efficiency and growth. Catherine T. Doherty has been appointed Senior VP for Regional Businesses, while Carrie E. Eglinton Manner takes on Senior VP for Advanced & General Diagnostics Clinical Solutions. Patrick T. Plewman is now Senior VP for Diagnostic Services, and Mark E. Delaney joins as Chief Commercial Officer. Additionally, Richard F. Adams steps in as VP and GM for Consumer Initiated Testing. The company aims to improve strategy execution and strengthen its leadership team.

Positive

• Appointment of experienced executives to key positions, enhancing operational efficiency.
• Focus on innovative diagnostic solutions and consumer testing, indicating potential growth areas.

Negative

• Retirement of CFO Mark Guinan raises uncertainties about financial leadership transition.

SECAUCUS, N.J., April 20, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has made several organizational changes and leadership appointments of seasoned executives to better support the company's two-point business strategy to accelerate growth and drive operational excellence:

• Catherine T. Doherty has been appointed Senior Vice President, Regional Businesses. Ms. Doherty has deep knowledge of the company's business, gained through three decades of leadership at the company. In this role Ms. Doherty will oversee regional and enterprise operations, the commercial organization, and marketing. She will also be responsible for driving operational excellence, including Program Drive, the company's quality, cost saving and productivity initiative. Ms. Doherty also co-chairs the company's Inclusion and Diversity Council.
     
• Carrie E. Eglinton Manner has been appointed Senior Vice President, Advanced & General Diagnostics Clinical Solutions. In her expanded role, Ms. Eglinton Manner is responsible for bringing innovative diagnostic solutions to market through Quest's clinical franchises. Before joining Quest, she had gained over two decades of leadership experience in healthcare and medical technology at GE Healthcare. Ms. Eglinton Manner co-chairs the company's African American Employee Business Network.
     
• Patrick T. Plewman, who had led Quest's West region and has been with Quest for more than nine years, is named to the new role of Senior Vice President, Diagnostic Services. He will lead a portfolio of data driven analytics and services businesses which enable employers, providers and others to deliver health care more effectively and efficiently. This portfolio includes Employer Population Health, Employer Solutions, ExamOne, Healthcare Analytic Solutions, and Quest HealthConnect, and recently acquired Pack Health. Mr. Plewman is also a member of the company's Environmental Working Group, a group of leaders charged with identifying new ways to enhance the company's approach to sustainability. Prior to joining Quest he held leadership, business development and strategy roles in molecular diagnostics at SmithKline Beecham and diaDexus.
      
• Mark E. Delaney has joined Quest as Senior Vice President and Chief Commercial Officer, responsible for all sales operations. Prior to joining Quest Diagnostics in March 2022, Mr. Delaney had been Vice President for Sales and Marketing at Hillrom for more than four years, and became Vice President and General Manager at Baxter after it acquired Hillrom. Previously, Mr. Delaney had held senior sales and marketing leadership roles at GE Healthcare, most recently as Senior Vice President and Zone Manager where he had regional responsibility for sales of imaging, patient monitoring, IT, and services.
     
• Richard F. Adams has joined Quest as Vice President and General Manager, Consumer Initiated Testing, a new role. Mr. Adams has extensive experience in e-commerce, digital marketing and customer experience, and will lead Quest's rapidly growing direct-to-consumer testing business.

Also, as previously announced, EVP and Chief Financial Officer Mark Guinan will retire in 2022, and the process to find a successor is underway.

"These initial actions are designed to improve our ability to execute our strategy, and position us well for continued growth," said Jim Davis, Quest Diagnostics CEO-elect.  "The transition is going well, and we're excited about the leadership that Mark Delaney and Richard Adams bring us."

"Jim and I believe these changes will help Quest grow and thrive in a post-pandemic world," said Steve Rusckowski, Chairman, CEO and President, who has announced he will transition his CEO and President roles to Mr. Davis on November 1. "These appointments demonstrate the depth and strength of Quest's management team."

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. Learn more at www.QuestDiagnostics.com or follow us on social media: LinkedIn, Twitter, Facebook and Instagram. For information on our COVID-19 testing, visit: newsroom.questdiagnostics.com/COVIDTestingUpdates

View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-announces-organizational-changes-to-accelerate-growth-and-drive-operational-excellence-301529497.html

SOURCE Quest Diagnostics

FAQ

What organizational changes were announced by Quest Diagnostics on April 20, 2022?

Quest Diagnostics revealed key leadership appointments and organizational changes aimed at accelerating growth and operational excellence.

Who are the new executives appointed at Quest Diagnostics?

Catherine T. Doherty, Carrie E. Eglinton Manner, Patrick T. Plewman, Mark E. Delaney, and Richard F. Adams are among the new executives appointed.

What is the strategic focus behind the leadership appointments at Quest Diagnostics?

The appointments aim to support Quest's business strategy to boost growth and enhance operational effectiveness.

When will Quest Diagnostics transition CEO roles?

The transition of CEO roles will occur on November 1, 2022.

What is the significance of the new role for Richard F. Adams at Quest Diagnostics?

Richard F. Adams will lead the rapidly growing direct-to-consumer testing business as VP and GM for Consumer Initiated Testing.